Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions
August 10th 2021
The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.